Chinese Researchers Develop MetaRing Biosensor for Ten Minute Breast Cancer Drug Sensitivity Profiling

Chinese researchers develop MetaRing, a SERS-based biosensor that identifies paclitaxel sensitivity in breast cancer patients with 92% accuracy in 10 minutes.

By: AXL Media

Published: Mar 26, 2026, 4:55 AM EDT

Source: Information for this report was sourced from the Hefei Institutes of Physical Science, Chinese Academy of Sciences and the journal Biosensors and Bioelectronics.

Overcoming the Latency of Conventional Chemosensitivity Testing

The effectiveness of chemotherapy is often hindered by inter-patient variability and tumor heterogeneity, making it difficult for oncologists to predict how a specific patient will respond to drugs like paclitaxel. Traditional drug sensitivity tests typically require large sample volumes and lengthy cell culture expansion periods, which can delay critical treatment decisions by days or weeks. To address this, the Hefei Institutes of Physical Science developed the MetaRing platform, a diagnostic tool designed to provide rapid, precise metabolic profiling directly from biopsy tissues or cell lysates, significantly shortening the window between diagnosis and personalized treatment.

The Physics of the Coffee-Ring Effect in Biosensing

The core innovation of MetaRing lies in its utilize of the "coffee-ring effect"—the physical phenomenon where evaporating liquid drives suspended particles to the edge of a droplet to form a ring-like pattern. By precisely controlling nanoparticle concentration and evaporation temperatures, the researchers achieved a deterministic assembly of nanoparticles into hierarchical structures. This engineered arrangement creates dense and stable "nanogaps" that are essential for high-performance sensing. Unlike previous biosensors that struggled with complex biological fluids, this matrix-robust design maintains its structural integrity and detection stability in water, buffer solutions, and protein-rich media.

Molecular Fingerprinting via SERS Technology

MetaRing integrates Surface-Enhanced Raman Spectroscopy (SERS) to capture the unique molecular "fingerprints" of tumor cells. When tumor cells are exposed to paclitaxel, their metabolic spectra shift in ways that reflect their sensitivity or resistance to the drug. The plasmonic ring structure of the MetaRing amplifies these signals, allowing the sensor to detect trace amounts of biological material without the need for fluorescent labeling. This sensitivity enables the acquisition of high-fidelity metabolic data from tiny biopsies, bypassing the need for the large-scale cell growth that slows down conventional testing methods.